EP2806871B1 - Compositions and methods for improving lactation - Google Patents
Compositions and methods for improving lactation Download PDFInfo
- Publication number
- EP2806871B1 EP2806871B1 EP13740771.4A EP13740771A EP2806871B1 EP 2806871 B1 EP2806871 B1 EP 2806871B1 EP 13740771 A EP13740771 A EP 13740771A EP 2806871 B1 EP2806871 B1 EP 2806871B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical agent
- serotonin
- agent
- lactation
- pthrp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 54
- 230000006651 lactation Effects 0.000 title claims description 25
- 238000000034 method Methods 0.000 title description 19
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 51
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 46
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims description 33
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 27
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical group C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 25
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims description 25
- 235000013336 milk Nutrition 0.000 claims description 25
- 210000004080 milk Anatomy 0.000 claims description 25
- 239000008267 milk Substances 0.000 claims description 25
- 239000008177 pharmaceutical agent Substances 0.000 claims description 23
- 241000282849 Ruminantia Species 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 14
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 229940076279 serotonin Drugs 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000013038 Hypocalcemia Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 230000000705 hypocalcaemia Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000004094 calcium homeostasis Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000862 serotonergic effect Effects 0.000 claims 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 2
- 241001465754 Metazoa Species 0.000 description 35
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 31
- 239000000463 material Substances 0.000 description 23
- 239000000126 substance Substances 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 239000000470 constituent Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 230000000153 supplemental effect Effects 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000005075 mammary gland Anatomy 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 210000004767 rumen Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 102100024819 Prolactin Human genes 0.000 description 5
- 108010057464 Prolactin Proteins 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 229940097325 prolactin Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 4
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000003674 animal food additive Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000006052 feed supplement Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- SGFBLYBOTWZDDE-UHFFFAOYSA-N Choline stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC[N+](C)(C)C SGFBLYBOTWZDDE-UHFFFAOYSA-N 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 2
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001849 choline stearate Drugs 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007275 epithelial homeostasis Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001983 lactogenic effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 235000011297 Brassica napobrassica Nutrition 0.000 description 1
- 241000219192 Brassica napus subsp. rapifera Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001502395 Ovibos moschatus Species 0.000 description 1
- 101150071808 PTHLH gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 235000019752 Wheat Middilings Nutrition 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000002264 animal mammary gland Anatomy 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000003213 brachydactyly type E2 Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 150000002231 fructose derivatives Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000004463 hay Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000004462 maize silage Substances 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011902 regulation of release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
- A23K40/35—Making capsules specially adapted for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands.
- Use of the serotonin agents results in increased PTHrP Levels, resulting in the release of calcium from the bone, which improves lactation.
- PTHrP Paraathyroid Hormone-related Protein
- PTHrP was originally discovered as the factor responsible for humoral hypercalcemia of malignancy, and is secreted from a variety of advanced soft tissue cancers.
- the N-terminal portion of PTHrP is similar to parathyroid hormone (PTH), and acts via the type 1 PTH receptors (PTH1R) to induce the receptor-activator of NFKB ligand (RANKL).
- PTH parathyroid hormone
- PTH1R type 1 PTH receptors
- RNKL receptor-activator of NFKB ligand
- PTHrP is undetectable in the circulation except during lactation, in advanced metastatic disease, or in patients with hyperprolactinemia.
- PRL prolactin
- 5-HT serotonin induced PTHrP expression in vascular smooth muscle cells.
- 5-HT serotonin induced PTHrP expression in vascular smooth muscle cells.
- the processes regulated by 5-HT include not only specialized mammary gland functions such as milk protein and milk lipid biogenesis, but also fundamental cell biological processes (i.e., apoptosis, barrier permeability, cell shedding).
- Epithelia lining other ductal/alveolar secretory organs also possess local 5-HT signaling systems, which have been implicated in various aspects of epithelial homeostasis.
- the present disclosure provides for methods and compositions for promoting calcium mobilization.
- the present invention provides for the use of pharmacological agents that are able to promote calcium mobilization, and which therefore prevent or treat conditions that are common in mammals, including dairy cattle and human females, at the onset of lactation.
- serotonin agonist a salt thereof or a composition containing serotonin agonist or a salt thereof for improving calcium mobilization of lactating animals.
- a feed for improving calcium mobilization of lactating animals comprising a composition containing serotonin agonist or a salt thereof and a stabilizer.
- a method for improving calcium mobilization of lactating animals comprising steps of producing a final feed by mixing a composition containing serotonin agonist or a salt thereof and a stabilizer with a suitable premix, which is a component of the final feed for animals.
- Another aspect of the invention is the use of a serotonin agonist in the manufacture of a medicament to increase ruminant serum calcium concentrations, and to increase ruminant milk quality and/or milk yield.
- the present invention provides the use of 5-HTP in the manufacture of a medicament to increase calcium mobilization in a ruminant animal.
- the present invention provides the use of 5-HTP in the manufacture of a medicament to increase lactation in a ruminant animal.
- One aspect of the invention provides for the use of 5-HTP in the manufacture of a medicament for the palliative, prophylactic or curative treatment of ruminant diseases associated with reduced calcium concentrations.
- the overall increase in ruminant milk yield, or the increase in peak milk yield, or the increase in milk quality is obtained from a dairy cow.
- the increase in ruminant milk quality and/or milk yield is obtained after administration of a serotonin agonist to a healthy ruminant.
- a serotonin agonist for increasing ruminant serum calcium concentration in the periparturient period.
- the present invention provides for the use of a serotonin agonist in the manufacture of a medicament to increase ruminant serum calcium concentrations, wherein the deficiencies of calcium levels in serum is prevented or alleviated.
- the present invention provides for the use of a serotonin agonist in the manufacture of a medicament for the palliative, prophylactic or curative treatment of ruminant diseases associated with reduced serum calcium concentrations, wherein periparturient hypocalcemia or milk fever, is prevented or alleviated.
- the improved calcium mobilization may also produce an increase in milk yields, fat-corrected milk yields, milk fat content therein and/or milk protein content therein.
- the composition comprises substantially 1-95 wt % serotonin agonist.
- the composition may comprise substantially 5-30 wt % serotonin agonist.
- the composition comprises substantially 1 to 80 wt % of the stabilizer.
- the stabilizer is preferably selected from a group including cyclodextrin or a derivative thereof.
- the composition may comprise substantially 10 wt % of the stabilizer.
- the composition further comprises ingredient(s) selected from a group including a bulking agent, a disintegration agent and a coated carrier.
- the coated carrier in some embodiments is a solid carrier, which is a coating soluble in intestines of the animals.
- the coated carrier suitably exhibits a multi-layer structure in the composition.
- the coated carrier is preferably adapted to remain undissolved at pH 1.5 to 3.5.
- the feed comprises other foodstuffs selected from a group including normal premix, cornmeal, cotton seed, wheat gluten, maize silage rutabaga, sugar beet pulp, apple pulp, ryegrass, fescue grass, alfalfa, feed concentrate and feed supplement.
- This invention makes use of stimulation of PTHrP by serotonin agonist compounds during the period of sensitivity to hypocalcemia.
- the invention is a method to administer serotonergic agents, such as a receptor agonist, releasing agent, reuptake inhibitor, inhibitor of degradation, or precursor chemical, with the intent and ultimate consequence that extraction of calcium from bone is accelerated.
- serotonergic agents such as a receptor agonist, releasing agent, reuptake inhibitor, inhibitor of degradation, or precursor chemical
- the person will administer (such as by intra-mammary infusion, injection, or feeding, a serotonergic agents) at a predetermined dose so as to activate calcium mobilization and prevent, or treat, periparturient hypocalcemia.
- TPI I 1 tryptophan hydroxylase 1
- 5-1 IT serotonin
- PTHrP parathyroid hormone-related peptide (a.k.a. parathyroid hormone-like hormone).
- 5-Hydroxytryptophan (5-HTP) also known as oxitripian (INN)
- INN oxitripian
- administer denote providing an additional amount of the substance into the animal's bloodstream on the indicated days, whether via daily or other injections on those days or by release on those days from a parenterally administered prolonged release delivery system (e.g., pellet, liquid depot, vaginal suppository or the like), or by continuous dosing (e.g., by an infusion pump) of the substance, delivered parenterally at the beginning of the time period, or, in the case of the continuous dose, throughout the time period.
- a parenterally administered prolonged release delivery system e.g., pellet, liquid depot, vaginal suppository or the like
- continuous dosing e.g., by an infusion pump
- animal is used herein to include all vertebrate animals, including humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages.
- production animals is used interchangeably with “livestock animals” and refers generally to animals raised primarily for food. For example, such animals include, but are not limited to, cattle (bovine), sheep (ovine), pigs (porcine or swine), poultry (avian), and the like.
- an effective amount of a supplemental constituent in compositions of the present invention can be an amount adequate to pass through the rumen to the post rumen digestive tract for provision of a desired effect. Desired effects can include, e.g., improved calcium mobilization, nutrition and health for the ruminant, pharmaceutical effects, effects on the composition of meat or milk, effects on the productivity of meat or milk, and/or the like.
- lactation means the production of milk and/or or secretion of milk by the mammary glands of a mammal or the period following giving birth during which milk is secreted in the breasts of a mammal.
- the term “mammal” means the Mammalia class of higher vertebrates.
- the term “mammal” includes, but is not limited to, a human. In one embodiment, the mammal is a ruminant animal.
- ruminant means an even-toed hoofed animal that has a complex 3-chamber or 4-chamber stomach and which typically rechews what it has previously swallowed.
- ruminants include cattle, sheep, goats, oxen, muskox, llamas, alpacas, guanicos, deer, bison, antelopes, camels, and giraffes.
- lipid refers, e.g., to any oil, fat, or substantially hydrophobic organic material.
- Lipid droplets or lipid particles in the filler composition or dispersed phase can include, e.g., oils, fats, monoglycerides, diglycerides, triglycerides, free fatty acids; corn oil, poppy seed oil, fish oil, cotton seed oil, soybean oil, walnut oil, safflower oil, sunflower oil, sesame oil, canola oil, linseed oil; free, esterified, or conjugated: oleic acid, linoleic acid, linolenic acid, phytanic acid, omega 3 fatty acids, eicosapentaenoic acid; lipid-containing materials, such as whole or modified oil seed or beans (such as soybeans), grape seeds, cotton seeds, safflower seeds; algae, microorganisms, yeasts, protozoa, etc.; and/or the like.
- pharmaceutically or “pharmacologically acceptable”, as used herein, refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
- pharmaceutically acceptable carrier includes any and all solvents, or a dispersion medium including, but not limited to, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be incorporated into such carriers.
- Supplemental constituents refers to constituents of a composite gel for protection through the rumen.
- Supplemental constituents can be present in the dispersed phase and/or the continuous phase of the composite gel.
- Certain supplemental constituents can play a role in the lipid or protein matrix structure of the composite gel.
- supplemental constituents are carried and protected by the lipid and/or matrix structure of the composite gel.
- Supplemental constituents can include, e.g., polyunsaturated fatty acids, monounsaturated fatty acids, free and esterified fatty acids, amino acids, proteins, pharmaceuticals, bioactive agents, nutrients, minerals, vitamins, antibiotics, and/or the like.
- supplemental constituents such as supplemental constituents, plasticizers, emulsifiers, stabilizers, anti-oxidants, redox-potential modifiers, minerals, texture modifiers, thickening agents, etc.
- supplemental constituents can range, e.g., from about zero percent to about 20 percent or more of the total suspension solids by weight.
- Such components can be, but are not limited to, materials such as natural or modified gums that are permitted for utilization in feed and food preparations, starches, modified starches, dextrins, maltodextrins, etc.
- Supplemental constituents that can be added to the matrix suspension include, e.g., vitamins, nutrients, amino acids, peptides, minerals, hormones, bioactive materials, bioengineered compounds, pharmaceuticals, and/or the like.
- rumen-bypass when used to characterize a substance, such as fat, protein, carbohydrate, etc., means the substance is naturally-resistant, to some degree, to alteration during passage of the rumen-bypass substance through the rumen of a ruminant and/or means the substance has been processed, treated, or associated with another material in some fashion that protects, to some degree, the rumen-bypass substance from alternation during passage of the rumen-bypass substance through the rumen of a ruminant.
- terapéuticaally effective amount of a compound means an amount that is effective to exhibit therapeutic or biological activity at the site(s) of activity in a ruminant, without undue adverse side effects (such as undue toxicity, irritation or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of the present invention.
- the serotonin agonist can be prepared in any type of appropriate medium for administration.
- the serotonin agonist can be provided together with physiologically tolerable liquid (e.g., saline), gel or solid carriers, diluents, adjuvant, excipients and as a rumen-protected encapsulated ingredient.
- physiologically tolerable liquid e.g., saline
- diluents and excipients include pharmaceutical grades of physiological saline, dextrose, glycerol, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like, and combinations thereof.
- compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents. These compositions typically contain 1%-95% of active ingredient, preferably 2%- 70%.
- the serotonin agonist can be incorporated into tablets, boluses, or capsules, and dosed to the patient.
- the serotonin agonist may also be incorporated into salt blocks and the like.
- the serotonin agonist can be added to feed as a freeze-dried powder or as an encapsulated composition that is protected from degradation in the rumen.
- the serotonin agonist is prepared in a solution of physiological phosphate-buffered saline (PBS) or for oral administration to a ruminant.
- PBS physiological phosphate-buffered saline
- the present invention provides for a method of treatment of a lactating mammal comprising the step of administering to the mammal a therapeutically effective amount of 5-hydroxytryptophan.
- the effective daily dosages of 5-HTP can range between about 5 mg and about 10.000 mg (e.g., between about 5 mg and 10,000 mg, 25 mg and about 2000 mg, about 50 mg and about 2000 mg, about 50 mg and about 1500 mg). In some cases, an effective daily dose of 5-HTP can range between about 25 mg to about 2500 mg.
- the serotonin agonist can be incorporated into tablets, drenches, boluses, capsules or premixes. Formulation of these active ingredients into such dosage forms can be accomplished by means of methods well known in the pharmaceutical formulation arts. See for example. U.S. Pat. No. 4,394,377 . Filling gelatin capsules with any desired form of the active ingredients readily produces capsules. If desired these materials can be diluted with an inert powdered diluent, such as sugar, starch, powdered milk, purified crystalline cellulose, or the like to increase the volume for convenience of filling capsules.
- an inert powdered diluent such as sugar, starch, powdered milk, purified crystalline cellulose, or the like to increase the volume for convenience of filling capsules.
- tablets may contain a base, a disintegrator, an absorbent, a binder, and a lubricant.
- Typical bases include lactose, sugar, sodium chloride, starch and mannitol.
- Starch is also a good disintegrator as is alginic acid.
- Surface-active agents such as sodium lauryl sulfate and dioctyl sodium sulphosuccinate are also sometimes used.
- Commonly used absorbents include starch and lactose. Magnesium carbonate is also useful for oily substances.
- binder there may be used, for example, gelatin, gums, starch, dextrin, polyvinyl pyrrolidone and various cellulose derivatives.
- lubricants are magnesium stearate, talc, paraffin wax, various metallic soaps, and polyethylene glycol.
- Drenches are prepared most readily by choosing a saline-suspended form of the serotonin agonist, fragments thereof or active molecules secreted therefrom.
- a water-soluble form of one ingredient may be used in conjunction with a water-insoluble form of the other by preparing a suspension of one with an aqueous solution of the other.
- Water-insoluble forms of either active ingredient may be prepared as a suspension or in some physiologically acceptable solvent such as polyethylene glycol.
- Suspensions of water-insoluble forms of either active ingredient can be prepared in oils such as peanut, corn, sesame oil or the like; in a glycol such as propylene glycol or a polyethylene glycol; or in water depending on the solubility of a particular active ingredient.
- Suitable physiologically acceptable adjuvants may be necessary in order to keep the active ingredients suspended.
- the adjuvants can be chosen from among the thickeners, such as carboxymethylcellulose, polyvinyl pyrrolidone, gelatin and the alginates.
- Surfactants generally will serve to suspend the active ingredients, particularly the fat-soluble propionate-enhancing compounds.
- Most useful for making suspensions in liquid nonsolvents are alkylphenol polyethylene oxide adducts, naphthalenesulfonates, alkylbenzene-sulfonates, and the polyoxyethylene sorbitan esters.
- many substances, which affect the hydrophilicity, density and surface tension of the liquid can assist in making suspensions in individual cases.
- silicone anti-foams, glycols, sorbitol, and sugars can be useful suspending agents.
- compositions of this invention may be separately administered, for example, by adding one directly to feed stuffs and co-administering the second material as a bolus tablet, drench, or capsule. Or each may be separately prepared and separately added to feed stuffs in appropriate quantities and at appropriate times.
- a material as choline stearate, a fatty acid complex, which may be used in the practice of this invention, may not be appropriate for incorporation into feed premixes because of its physical characteristics.
- the choline stearate composition could be provided separately in a suitable diluent such as, for example, corn flour, ground corn cob, hominy, corn glutenmeal, wheat middlings, soybean meal, soybean mill feed, rice mill byproduct, and the like and mixtures thereof.
- a suitable diluent such as, for example, corn flour, ground corn cob, hominy, corn glutenmeal, wheat middlings, soybean meal, soybean mill feed, rice mill byproduct, and the like and mixtures thereof.
- suitable diluents may be found in U.S. Pat. No. 4,394,377 .
- the serotonin agonist may be administered to an animal in a composition, a premix, that is then mixed into the animal feed supply.
- a composition may comprise the serotonin agonist alone or the serotonin agonist may be mixed with a carrier and/or with other drugs, vitamins, minerals, protein concentrates and similar feed supplements.
- These compositions may be prepared in dry granular powder form, as pellets, in the form of pastes, encapsulated to be rumen protected, or may be formulated as liquid feed supplements and the like. Any type of feed may be medicated with such compositions, including common dry feed, liquid feeds, and pelleted feeds.
- the methods of formulating supplemental materials into animal feeds are well known.
- compositions of the invention may be used as a feed additive premix, feed additive concentrate or feed additive supplement in which the active ingredients are distributed uniformly throughout a standard organic or inorganic animal feed carrier in a concentrated form which is conveniently packaged and shipped to the feed mixer.
- the grower or the feed mixer then in turn mixes this premix, concentrate or supplement uniformly with a normal diet for the animal as desired.
- carriers for premix compositions are soybean meal, corn oil, ground corn, barley, wheat, mineral mixtures containing, e.g., vermiculite or diatomaceous earth, corn gluten meal, soy flour or other modestly priced edible ingredients.
- the serotonin agonist may also be admixed with a suitable carrier such as an edible feed or feed component in the form of a feed additive supplement.
- a suitable carrier such as an edible feed or feed component in the form of a feed additive supplement.
- edible feed components are feed fortifiers and enhancers for preruminant bovine calves of any of the kinds disclosed in U.S. Pat. No. 6,156,333 .
- the serotonin agonist is provided according to the anticipated daily consumption of the supplement to provide a daily dose of each of these ingredients in one of the ranges specified.
- the serotonin agonist may be incorporated directly into feeds by a mill or other feed supplier to provide a finished feed product to the grower.
- a finished feed product could be made up of any of the various grains, lucerne, grasses, minerals, vitamins, protein supplements, drugs and the like which go into the formulation of a nutritionally complete ruminant feed.
- the serotonin agonist may be mixed directly with cattle feed made up of various components such as hay, straw, silage, cornstalks, cottonseed hulls, grain, oats, barley and cereal brans, particularly for the ruminants; antioxidants, minerals, vitamins, anthelmintics, and other appropriate medicaments. See U.S. Pat. No. 4,394,377 .
- the serotonin agonist may be incorporated into a liquid feed for preruminant bovine calves of any of the kinds disclosed in U.S. Pat. No. 6,156,333 .
- the serotonin agonist may be mixed into a suitable animal feed by any method appropriate for mixing a micronutrient or micro-component into animal feed. Examples of such methods include but are not limited to the following: spraying the serotonin agonist onto dry feed and mechanically mixing the serotonin agonist into dry or liquid feed; top dress grain or concentrate mix.
- the serotonin agonist may be administered in any manner consistent with the present invention.
- the serotonin agonist is typically given in an amount of approximately 50/kg mg to 500 mg/kg, with about 100 mg being preferable.
- this amount of serotonin agonist can be delivered in a variety of ways and at a number of different dose levels (depending on the frequency of administration).
- the serotonin agonist is administered in a sustained-release formulation.
- the serotonin agonist is administered to the animal until at least day 4 of the treatment, even more preferably until at least day 10 (e.g. on days 0, 2, 4, 6, 8, 10).
- any natural or synthetic analog of 5-HTP having approximately the equivalent bioactivity of the 5-HTP native to the animal may also be used.
- Approximately equivalent bioactivity as used herein would be at least 50% of the bioactivity of the 5-HTP.
- Preferably such analog would have at least 75% of the equivalent bioactivity, more preferably 90% of the equivalent bioactivity and most preferably 100% or greater than 100% of the bioactivity equivalent to the 5-HTP.
- the serotonin agonist-containing composition may also comprise 1 to 90 wt % of fillers although a preferable workable range of 1 to 60 wt % and a more preferable workable range of 1 to 40 wt % of the fillers may also be used in the composition.
- the actual content will depend on the actual amount of serotonin agonist and inclusion compound host materials used.
- the fillers may be selected from a group including powdered cellulose, starch and calcium sulfate (e.g.
- the serotonin agonist-containing composition may also comprise 5 to 50 wt % of disintegrants and binders although a preferable workable range of 10 to 40 wt % and a more preferable workable range of 15 to 35 wt % may also be used.
- the actual content will depend on the actual amount of serotonin agonist, the inclusion compound host material and other ingredients used.
- the binders and disintegrants may be selected from a group including hydropropyl starch, microbial alginate, microcrystalline cellulose and starch. It has been identified that if the content of the disintegrants and binders in the composition is less than 5 wt %, granules of the composition produced will lack the required hardness.
- the resulting composition will have excessive hardness, this is especially so if the content of binders represent a large portion of the mixture of the disintegrants and binders. This will result in reduced absorption of the composition by the intestines of the animals.
- the serotonin agonist-containing composition may also comprise 0.05 to 0.3 wt % of flavoring and smelling agents which may be a flavoring essence.
- the serotonin agonist-containing composition may also comprise 1 to 20 wt % of coating materials although a preferable workable range is 1 to 15 wt % and a more preferable workable range is 2 to 10 wt %.
- the actual content will depend on the actual amount of serotonin agonist, the inclusion compound host materials and the other ingredients used.
- the coating materials are preferably enteric-coated which allows dissolution in an alkaline environment such as in the intestines.
- the coating materials may be made of and selected from a group including cellulose acetate phthalate, starch acetate phthalate, methyl cellulose phthalate, glucose or fructose derivatives from phthalic acid, acrylic and methacrylic copolymers, polymethyl vinyl ether, partly esterified substance of maleic anhydride copolymers, lac and formogelatine. It has been identified that if the content of the coating materials is less than 1 wt %, granules of the composition may not be entirely covered by the coating materials, which act as a protective layer. The serotonin agonist-containing composition may thus degrade before being absorbed by the intestines into the bloodstream of the animals. On the other hand, if the content of the coating materials exceeds 15 wt %, the active ingredients in the composition may not effectively be released from the composition. Thus, the intended regulation of calcium mobilization would not be achieved.
- TPI1 -/- TPI1 -/- , and corresponding wild type control animals (C57BL/6J genetic background) were bred and maintained in our animal facility. All experiments were performed under protocols approved by the University of Cincinnati Institutional Animal Care and Use Committee. Plasma was collected for PTHrP assay from non-lactating wild type mice and both wild type and TPH1 -/- animals on day 10 of lactation. Mammary gland tissues (#4 glands counted from most rostral) were collected for immunostaining from TPH1 -/- animals and wild type controls on day 10 of lactation, and were fixed in 4% paraformaldehyde, before being paraffin embedded and sectioned.
- Plasma PTHrP IRMA Plasma PTHrP IRMA. Plasma PTHrP levels were measured using a two-site immunoradiometric assay specific for PTHrP 1-86 (Becton Dickinson), following the manufacturer's instructions. The detection limit (blank serum +1 standard deviation) was 0.3 pM under the conditions of this assay.
- pBMEC Primary bovine mammary epithelial cells
- RNA quality was determined through spectrophometric methods on the Nanodrop 2000 (Thermo Scientific). A total of 1 pg was reverse transcribed using the QuantiTect reverse transcription kit (Qiagen). Quantitative real-time RT-PCR was performed using the Applied Biosystems Step One Plus system (Applied Biosystems) using fast SYBR green master mix (Applied Biosystems). The following conditions were utilized: 95'C for 20 sec. followed by 40 cycles of 95'C for 3 sec., 60'C for 30 sec.
- PTHrP fluorescent immunostaining was performed using a 1:50dilution of goat anti-PTHrP (N-19; Santa Cruz Biotechnology) overnight at 4'C and 1:1000 dilution of the rabbit anti-goat Alexa Fluor 488 Fa(b) fragments (Invitrogen) for 30 min at room temperature on paraffin-embedded sections of mammary gland tissue collected from TPH1 -/- and wild type (TPH1 +/+ ) mice collected at day 10 of lactation. Nuclei were visualized using a 1:1000 dilution of TOPRO-3 (Invitrogen) for 20 min at room temperature. Fluorescence was visualized on a Zeiss LSM 10 confocal microscope.
- PTHrP was below the level of detectability in the blood plasma of non-lactating females, and was readily detectable during lactation
- 5-HTP 5-hydroxytryptophan
- the conversion of L-tryptophan to 5-hydroxytryptophan (5-HTP) is the rate-limiting step in 5-HT synthesis; therefore we injected 5-HTP to bypass the enzyme deficiency in TPH1 mice, and measured PTHrP plasma levels.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
- This research was made possible by funding from the NRI Competitive Grant 02008-35206-17898 from the USDA. The government may have certain rights in this invention.
- The present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands. Use of the serotonin agents results in increased PTHrP Levels, resulting in the release of calcium from the bone, which improves lactation.
- The transition from pregnancy to lactation in mammals is a critical period for calcium homeostasis. Approximately 5% of all dairy animals experience severe periparturient hypocalcemia, also known as milk fever. This number increases to approximately 50% in older cows, and the highest-producing cows are at highest risk of this pathology. At calving, there is a 4-5% increase in plasma calcium clearance, with calcium replacement coming from the mobilization of calcium from bone. Similar bone calcium mobilization occurs in human women during the periparturient period.
- The specific mobilization of bone in lactation is driven by a hormone named "Parathyroid Hormone-related Protein (PTHrP, gene symbol PTHLH, also known as HHM; PLP; BDE2; PTHR; PTHRP)." A failure to maintain calcium homeostasis during the transition lo milk secretion is at the heart of periparturient hypocalcemia.
- PTHrP was originally discovered as the factor responsible for humoral hypercalcemia of malignancy, and is secreted from a variety of advanced soft tissue cancers. The N-terminal portion of PTHrP is similar to parathyroid hormone (PTH), and acts via the
type 1 PTH receptors (PTH1R) to induce the receptor-activator of NFKB ligand (RANKL). - PTHrP is undetectable in the circulation except during lactation, in advanced metastatic disease, or in patients with hyperprolactinemia. In spite of obvious correlations with states of elevated prolactin (PRL), PRL did not induce PTHrP in conventional cell cultures of mammary epithelium, and our lab has done numerous experiments that confirmed that PRL does not induce PTHrP in mammary cells by a direct mechanism.
- A previous study showed that serotonin (5-HT) induced PTHrP expression in vascular smooth muscle cells. In the mammary glands 5-HT regulates key aspects of epithelial homeostasis by autocrine-paracrine signaling. The processes regulated by 5-HT include not only specialized mammary gland functions such as milk protein and milk lipid biogenesis, but also fundamental cell biological processes (i.e., apoptosis, barrier permeability, cell shedding). Epithelia lining other ductal/alveolar secretory organs also possess local 5-HT signaling systems, which have been implicated in various aspects of epithelial homeostasis.
- It has now been shown that serotonin, synthesized within the mammary gland, is responsible for causing the increase in PTHrP associated with the onset of lactation. Consequently, drugs that increase serotonin signaling are useful for maintaining healthy calcium levels in lactating females. US Patent specification no.
US2003/139420A1 discloses a method for enhancing lactation in a mammal comprising administering an effective amount of a pharmaceutically active agent. A publication by R. L. Horst et al "Strategies for Preventing Milk Fever in Dairy Cattle" J Dairy Sci, 1 January 1997, pages 1269-1280 reviews various factors that predispose cows to milk fever and strategies for the prevention of milk fever. - In one aspect, the present disclosure provides for methods and compositions for promoting calcium mobilization.
- In another embodiment, the present invention provides for the use of pharmacological agents that are able to promote calcium mobilization, and which therefore prevent or treat conditions that are common in mammals, including dairy cattle and human females, at the onset of lactation.
- In one embodiment of the present invention, there is provided the use of serotonin agonist, a salt thereof or a composition containing serotonin agonist or a salt thereof for improving calcium mobilization of lactating animals.
- In another embodiment of the present invention, there is provided a feed for improving calcium mobilization of lactating animals comprising a composition containing serotonin agonist or a salt thereof and a stabilizer.
- In another embodiment of the present invention, there is provided a method for improving calcium mobilization of lactating animals comprising steps of producing a final feed by mixing a composition containing serotonin agonist or a salt thereof and a stabilizer with a suitable premix, which is a component of the final feed for animals.
- Another aspect of the invention is the use of a serotonin agonist in the manufacture of a medicament to increase ruminant serum calcium concentrations, and to increase ruminant milk quality and/or milk yield.
- The present invention provides the use of 5-HTP in the manufacture of a medicament to increase calcium mobilization in a ruminant animal.
- The present invention provides the use of 5-HTP in the manufacture of a medicament to increase lactation in a ruminant animal.
- One aspect of the invention provides for the use of 5-HTP in the manufacture of a medicament for the palliative, prophylactic or curative treatment of ruminant diseases associated with reduced calcium concentrations.
- In another specific embodiment, the overall increase in ruminant milk yield, or the increase in peak milk yield, or the increase in milk quality, is obtained from a dairy cow.
- In one aspect of the invention, the increase in ruminant milk quality and/or milk yield is obtained after administration of a serotonin agonist to a healthy ruminant.
- In another aspect of the invention, there is provided a serotonin agonist for increasing ruminant serum calcium concentration in the periparturient period.
- In one embodiment, the present invention provides for the use of a serotonin agonist in the manufacture of a medicament to increase ruminant serum calcium concentrations, wherein the deficiencies of calcium levels in serum is prevented or alleviated.
- In another embodiment, the present invention provides for the use of a serotonin agonist in the manufacture of a medicament for the palliative, prophylactic or curative treatment of ruminant diseases associated with reduced serum calcium concentrations, wherein periparturient hypocalcemia or milk fever, is prevented or alleviated.
- The improved calcium mobilization may also produce an increase in milk yields, fat-corrected milk yields, milk fat content therein and/or milk protein content therein.
- In one embodiment, the composition comprises substantially 1-95 wt % serotonin agonist. In particular, the composition may comprise substantially 5-30 wt % serotonin agonist.
- In one embodiment, the composition comprises substantially 1 to 80 wt % of the stabilizer. The stabilizer is preferably selected from a group including cyclodextrin or a derivative thereof. In particular, the composition may comprise substantially 10 wt % of the stabilizer.
- In one embodiment, the composition further comprises ingredient(s) selected from a group including a bulking agent, a disintegration agent and a coated carrier. In one embodiment, the coated carrier in some embodiments is a solid carrier, which is a coating soluble in intestines of the animals. The coated carrier suitably exhibits a multi-layer structure in the composition. The coated carrier is preferably adapted to remain undissolved at pH 1.5 to 3.5.
- In some embodiments, the feed comprises other foodstuffs selected from a group including normal premix, cornmeal, cotton seed, wheat gluten, maize silage rutabaga, sugar beet pulp, apple pulp, ryegrass, fescue grass, alfalfa, feed concentrate and feed supplement.
- The mention of use of compounds in the present invention, shall at all times be understood to include all active forms of such compounds, including, for example, the free form thereof, e.g., the free acid or base form, and also, all prodrugs, polymorphs, hydrates, solvates, tautomers, stereoisomers, e.g., diastereomers and enantiomers, and the like, and all pharmaceutically acceptable salts as described above, unless specifically stated otherwise. It will also be appreciated that the use of suitable active metabolites of such compounds, in any suitable form, are also included herein.
- This invention makes use of stimulation of PTHrP by serotonin agonist compounds during the period of sensitivity to hypocalcemia. The invention is a method to administer serotonergic agents, such as a receptor agonist, releasing agent, reuptake inhibitor, inhibitor of degradation, or precursor chemical, with the intent and ultimate consequence that extraction of calcium from bone is accelerated. The person will administer (such as by intra-mammary infusion, injection, or feeding, a serotonergic agents) at a predetermined dose so as to activate calcium mobilization and prevent, or treat, periparturient hypocalcemia.
- These and other features are explained more fully in the embodiments illustrated below. It should be understood that in general the features of one embodiment also may be used in combination with features of another embodiment and that the embodiments are not intended to limit the scope of the invention.
- The various exemplary embodiments of the present invention, which will become more apparent as the description proceeds, are described in the following detailed description in conjunction with the accompanying drawings, in which:
-
FIG. 1 depicts the circulating levels of (A) serum 5-HT and (B) plasma PTHrP in rats fed 0.2% 5-HTP from d13 pregnancy through d9 lactation compared to rats fed a control breeder diet. -
FIG. 2 depicts the serum and milk calcium concentrations in rats fed 0.2% 5-HTP (n=15) from d13 pregnancy-d9 Lactation compared to rats fed a control (n=15) breeder diet al (A)day 1 of lactation and (B) day 9 of lactation. - Abbreviations used are TPI I 1:
tryptophan hydroxylase 1; 5-1 IT: serotonin; PTHrP: parathyroid hormone-related peptide (a.k.a. parathyroid hormone-like hormone). 5-Hydroxytryptophan (5-HTP), also known as oxitripian (INN), is a naturally occurring amino acid and chemical precursor as well as a metabolic intermediate in the biosynthesis of the neurotransmitters serotonin and melatonin from tryptophan. - As used in this specification and the appended claims, the singular forms "a", "an" and "the" can include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a component" can include a combination of two or more components; a reference to "containers" can include individual containers, and the like.
- Although many methods and materials similar, modified, or equivalent to those described herein can be used in the practice of the present invention without undue experimentation, the preferred materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
- As used herein the terms "administer", "administered", and "administration" of the various substances (e.g., 5-HTP) denote providing an additional amount of the substance into the animal's bloodstream on the indicated days, whether via daily or other injections on those days or by release on those days from a parenterally administered prolonged release delivery system (e.g., pellet, liquid depot, vaginal suppository or the like), or by continuous dosing (e.g., by an infusion pump) of the substance, delivered parenterally at the beginning of the time period, or, in the case of the continuous dose, throughout the time period. Alternatively it may refer to the delivery of the dosage by periodic (e.g. daily) parenteral injection or implantation or the like.
- The term "animal" is used herein to include all vertebrate animals, including humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages. As used herein, the term "production animals" is used interchangeably with "livestock animals" and refers generally to animals raised primarily for food. For example, such animals include, but are not limited to, cattle (bovine), sheep (ovine), pigs (porcine or swine), poultry (avian), and the like.
- The term "effective amount", as used herein, refers to an amount of specified material adequate to provide a desired effect. For example, an effective amount of a supplemental constituent in compositions of the present invention can be an amount adequate to pass through the rumen to the post rumen digestive tract for provision of a desired effect. Desired effects can include, e.g., improved calcium mobilization, nutrition and health for the ruminant, pharmaceutical effects, effects on the composition of meat or milk, effects on the productivity of meat or milk, and/or the like.
- As used here and, the term "lactation" means the production of milk and/or or secretion of milk by the mammary glands of a mammal or the period following giving birth during which milk is secreted in the breasts of a mammal.
- As used herein, the term "mammal" means the Mammalia class of higher vertebrates. The term "mammal" includes, but is not limited to, a human. In one embodiment, the mammal is a ruminant animal.
- As used herein, the term "ruminant" means an even-toed hoofed animal that has a complex 3-chamber or 4-chamber stomach and which typically rechews what it has previously swallowed. Some non-exhaustive examples of ruminants include cattle, sheep, goats, oxen, muskox, llamas, alpacas, guanicos, deer, bison, antelopes, camels, and giraffes.
- The term "lipid", as used herein, refers, e.g., to any oil, fat, or substantially hydrophobic organic material. Lipid droplets or lipid particles in the filler composition or dispersed phase can include, e.g., oils, fats, monoglycerides, diglycerides, triglycerides, free fatty acids; corn oil, poppy seed oil, fish oil, cotton seed oil, soybean oil, walnut oil, safflower oil, sunflower oil, sesame oil, canola oil, linseed oil; free, esterified, or conjugated: oleic acid, linoleic acid, linolenic acid, phytanic acid, omega 3 fatty acids, eicosapentaenoic acid; lipid-containing materials, such as whole or modified oil seed or beans (such as soybeans), grape seeds, cotton seeds, safflower seeds; algae, microorganisms, yeasts, protozoa, etc.; and/or the like.
- The term "pharmaceutically" or "pharmacologically acceptable", as used herein, refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
- The term, "pharmaceutically acceptable carrier", as used herein, includes any and all solvents, or a dispersion medium including, but not limited to, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be incorporated into such carriers.
- The term "supplemental constituents" or "supplementary bioactive ingredients", as used herein, refers to constituents of a composite gel for protection through the rumen. Supplemental constituents can be present in the dispersed phase and/or the continuous phase of the composite gel. Certain supplemental constituents can play a role in the lipid or protein matrix structure of the composite gel. Optionally, supplemental constituents are carried and protected by the lipid and/or matrix structure of the composite gel. Supplemental constituents can include, e.g., polyunsaturated fatty acids, monounsaturated fatty acids, free and esterified fatty acids, amino acids, proteins, pharmaceuticals, bioactive agents, nutrients, minerals, vitamins, antibiotics, and/or the like.
- Other constituents, such as supplemental constituents, plasticizers, emulsifiers, stabilizers, anti-oxidants, redox-potential modifiers, minerals, texture modifiers, thickening agents, etc., can range, e.g., from about zero percent to about 20 percent or more of the total suspension solids by weight. Such components can be, but are not limited to, materials such as natural or modified gums that are permitted for utilization in feed and food preparations, starches, modified starches, dextrins, maltodextrins, etc. Supplemental constituents that can be added to the matrix suspension include, e.g., vitamins, nutrients, amino acids, peptides, minerals, hormones, bioactive materials, bioengineered compounds, pharmaceuticals, and/or the like.
- As used herein, the terms "rumen-bypass," rumen-inert," and rumen-protected," when used to characterize a substance, such as fat, protein, carbohydrate, etc., means the substance is naturally-resistant, to some degree, to alteration during passage of the rumen-bypass substance through the rumen of a ruminant and/or means the substance has been processed, treated, or associated with another material in some fashion that protects, to some degree, the rumen-bypass substance from alternation during passage of the rumen-bypass substance through the rumen of a ruminant.
- As used herein, "therapeutically effective amount of a compound" means an amount that is effective to exhibit therapeutic or biological activity at the site(s) of activity in a ruminant, without undue adverse side effects (such as undue toxicity, irritation or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of the present invention.
- It is not intended that the present invention be limited by the particular nature of the therapeutic preparation. The serotonin agonist can be prepared in any type of appropriate medium for administration. For example, the serotonin agonist can be provided together with physiologically tolerable liquid (e.g., saline), gel or solid carriers, diluents, adjuvant, excipients and as a rumen-protected encapsulated ingredient. Suitable diluents and excipients include pharmaceutical grades of physiological saline, dextrose, glycerol, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents. These compositions typically contain 1%-95% of active ingredient, preferably 2%- 70%. The serotonin agonist can be incorporated into tablets, boluses, or capsules, and dosed to the patient. The serotonin agonist may also be incorporated into salt blocks and the like. The serotonin agonist can be added to feed as a freeze-dried powder or as an encapsulated composition that is protected from degradation in the rumen. In one embodiment, the serotonin agonist is prepared in a solution of physiological phosphate-buffered saline (PBS) or for oral administration to a ruminant.
- In one embodiment, the present invention provides for a method of treatment of a lactating mammal comprising the step of administering to the mammal a therapeutically effective amount of 5-hydroxytryptophan. In one embodiment, the effective daily dosages of 5-HTP can range between about 5 mg and about 10.000 mg (e.g., between about 5 mg and 10,000 mg, 25 mg and about 2000 mg, about 50 mg and about 2000 mg, about 50 mg and about 1500 mg). In some cases, an effective daily dose of 5-HTP can range between about 25 mg to about 2500 mg.
- The serotonin agonist can be incorporated into tablets, drenches, boluses, capsules or premixes. Formulation of these active ingredients into such dosage forms can be accomplished by means of methods well known in the pharmaceutical formulation arts. See for example.
U.S. Pat. No. 4,394,377 . Filling gelatin capsules with any desired form of the active ingredients readily produces capsules. If desired these materials can be diluted with an inert powdered diluent, such as sugar, starch, powdered milk, purified crystalline cellulose, or the like to increase the volume for convenience of filling capsules. - Conventional formulation processes can be used to prepare tablets containing the serotonin agonist. In addition to the active ingredients, tablets may contain a base, a disintegrator, an absorbent, a binder, and a lubricant. Typical bases include lactose, sugar, sodium chloride, starch and mannitol. Starch is also a good disintegrator as is alginic acid. Surface-active agents such as sodium lauryl sulfate and dioctyl sodium sulphosuccinate are also sometimes used. Commonly used absorbents include starch and lactose. Magnesium carbonate is also useful for oily substances. As a binder there may be used, for example, gelatin, gums, starch, dextrin, polyvinyl pyrrolidone and various cellulose derivatives. Among the commonly used lubricants are magnesium stearate, talc, paraffin wax, various metallic soaps, and polyethylene glycol.
- Drenches are prepared most readily by choosing a saline-suspended form of the serotonin agonist, fragments thereof or active molecules secreted therefrom. A water-soluble form of one ingredient may be used in conjunction with a water-insoluble form of the other by preparing a suspension of one with an aqueous solution of the other. Water-insoluble forms of either active ingredient may be prepared as a suspension or in some physiologically acceptable solvent such as polyethylene glycol. Suspensions of water-insoluble forms of either active ingredient can be prepared in oils such as peanut, corn, sesame oil or the like; in a glycol such as propylene glycol or a polyethylene glycol; or in water depending on the solubility of a particular active ingredient. Suitable physiologically acceptable adjuvants may be necessary in order to keep the active ingredients suspended. The adjuvants can be chosen from among the thickeners, such as carboxymethylcellulose, polyvinyl pyrrolidone, gelatin and the alginates. Surfactants generally will serve to suspend the active ingredients, particularly the fat-soluble propionate-enhancing compounds. Most useful for making suspensions in liquid nonsolvents are alkylphenol polyethylene oxide adducts, naphthalenesulfonates, alkylbenzene-sulfonates, and the polyoxyethylene sorbitan esters. In addition many substances, which affect the hydrophilicity, density and surface tension of the liquid, can assist in making suspensions in individual cases. For example, silicone anti-foams, glycols, sorbitol, and sugars can be useful suspending agents.
- Additionally the subject compositions of this invention may be separately administered, for example, by adding one directly to feed stuffs and co-administering the second material as a bolus tablet, drench, or capsule. Or each may be separately prepared and separately added to feed stuffs in appropriate quantities and at appropriate times. For example, such a material as choline stearate, a fatty acid complex, which may be used in the practice of this invention, may not be appropriate for incorporation into feed premixes because of its physical characteristics. In such an instance the choline stearate composition could be provided separately in a suitable diluent such as, for example, corn flour, ground corn cob, hominy, corn glutenmeal, wheat middlings, soybean meal, soybean mill feed, rice mill byproduct, and the like and mixtures thereof. A description of such suitable diluents may be found in
U.S. Pat. No. 4,394,377 . - The serotonin agonist may be administered to an animal in a composition, a premix, that is then mixed into the animal feed supply. Such a composition may comprise the serotonin agonist alone or the serotonin agonist may be mixed with a carrier and/or with other drugs, vitamins, minerals, protein concentrates and similar feed supplements. These compositions may be prepared in dry granular powder form, as pellets, in the form of pastes, encapsulated to be rumen protected, or may be formulated as liquid feed supplements and the like. Any type of feed may be medicated with such compositions, including common dry feed, liquid feeds, and pelleted feeds. The methods of formulating supplemental materials into animal feeds are well known. It is necessary only to calculate the amount of each compound, which it is desired to administer to each animal, to take into account the amount of feed per day that the animal eats and then mix in the appropriate amount of the serotonin agonist. See
U.S. Pat. No. 4,394,377 . - The compositions of the invention may be used as a feed additive premix, feed additive concentrate or feed additive supplement in which the active ingredients are distributed uniformly throughout a standard organic or inorganic animal feed carrier in a concentrated form which is conveniently packaged and shipped to the feed mixer. The grower or the feed mixer then in turn mixes this premix, concentrate or supplement uniformly with a normal diet for the animal as desired. Examples of carriers for premix compositions are soybean meal, corn oil, ground corn, barley, wheat, mineral mixtures containing, e.g., vermiculite or diatomaceous earth, corn gluten meal, soy flour or other modestly priced edible ingredients.
- The serotonin agonist may also be admixed with a suitable carrier such as an edible feed or feed component in the form of a feed additive supplement. Examples of such edible feed components are feed fortifiers and enhancers for preruminant bovine calves of any of the kinds disclosed in
U.S. Pat. No. 6,156,333 . If to be fed free choice or as a supplement, The serotonin agonist is provided according to the anticipated daily consumption of the supplement to provide a daily dose of each of these ingredients in one of the ranges specified. - In addition, the serotonin agonist may be incorporated directly into feeds by a mill or other feed supplier to provide a finished feed product to the grower. A finished feed product could be made up of any of the various grains, lucerne, grasses, minerals, vitamins, protein supplements, drugs and the like which go into the formulation of a nutritionally complete ruminant feed. The serotonin agonist may be mixed directly with cattle feed made up of various components such as hay, straw, silage, cornstalks, cottonseed hulls, grain, oats, barley and cereal brans, particularly for the ruminants; antioxidants, minerals, vitamins, anthelmintics, and other appropriate medicaments. See
U.S. Pat. No. 4,394,377 . Alternatively, The serotonin agonist may be incorporated into a liquid feed for preruminant bovine calves of any of the kinds disclosed inU.S. Pat. No. 6,156,333 . - The serotonin agonist may be mixed into a suitable animal feed by any method appropriate for mixing a micronutrient or micro-component into animal feed. Examples of such methods include but are not limited to the following: spraying the serotonin agonist onto dry feed and mechanically mixing the serotonin agonist into dry or liquid feed; top dress grain or concentrate mix.
- One of ordinary skill in the art will appreciate that the serotonin agonist may be administered in any manner consistent with the present invention. The serotonin agonist is typically given in an amount of approximately 50/kg mg to 500 mg/kg, with about 100 mg being preferable. The skilled artisan will appreciate that this amount of serotonin agonist can be delivered in a variety of ways and at a number of different dose levels (depending on the frequency of administration). In one embodiment the serotonin agonist is administered in a sustained-release formulation. In another embodiment, the serotonin agonist is administered to the animal until at least day 4 of the treatment, even more preferably until at least day 10 (e.g. on
days 0, 2, 4, 6, 8, 10). - Those skilled in the art will also recognize that any natural or synthetic analog of 5-HTP having approximately the equivalent bioactivity of the 5-HTP native to the animal may also be used. Approximately equivalent bioactivity as used herein would be at least 50% of the bioactivity of the 5-HTP. Preferably such analog would have at least 75% of the equivalent bioactivity, more preferably 90% of the equivalent bioactivity and most preferably 100% or greater than 100% of the bioactivity equivalent to the 5-HTP.
- The serotonin agonist-containing composition may also comprise 1 to 90 wt % of fillers although a preferable workable range of 1 to 60 wt % and a more preferable workable range of 1 to 40 wt % of the fillers may also be used in the composition. The actual content will depend on the actual amount of serotonin agonist and inclusion compound host materials used. The fillers may be selected from a group including powdered cellulose, starch and calcium sulfate (e.g. CaSO4.2H2O) It is to be noted that if the content of the fillers exceeds 90 wt % in the serotonin agonist-containing composition, the content of the main active ingredients will thus be reduced, and the serotonin agonist-containing composition may become ineffective in improving calcium mobilization of the animals fed with a feed mixed therewith.
- The serotonin agonist-containing composition may also comprise 5 to 50 wt % of disintegrants and binders although a preferable workable range of 10 to 40 wt % and a more preferable workable range of 15 to 35 wt % may also be used. The actual content will depend on the actual amount of serotonin agonist, the inclusion compound host material and other ingredients used. The binders and disintegrants may be selected from a group including hydropropyl starch, microbial alginate, microcrystalline cellulose and starch. It has been identified that if the content of the disintegrants and binders in the composition is less than 5 wt %, granules of the composition produced will lack the required hardness. In addition, manufacturing of the composition would become very difficult. If however the content of the disintegrants and binders is more than 50 wt %, the resulting composition will have excessive hardness, this is especially so if the content of binders represent a large portion of the mixture of the disintegrants and binders. This will result in reduced absorption of the composition by the intestines of the animals.
- The serotonin agonist-containing composition may also comprise 0.05 to 0.3 wt % of flavoring and smelling agents which may be a flavoring essence.
- The serotonin agonist-containing composition may also comprise 1 to 20 wt % of coating materials although a preferable workable range is 1 to 15 wt % and a more preferable workable range is 2 to 10 wt %. The actual content will depend on the actual amount of serotonin agonist, the inclusion compound host materials and the other ingredients used. The coating materials are preferably enteric-coated which allows dissolution in an alkaline environment such as in the intestines. The coating materials may be made of and selected from a group including cellulose acetate phthalate, starch acetate phthalate, methyl cellulose phthalate, glucose or fructose derivatives from phthalic acid, acrylic and methacrylic copolymers, polymethyl vinyl ether, partly esterified substance of maleic anhydride copolymers, lac and formogelatine. It has been identified that if the content of the coating materials is less than 1 wt %, granules of the composition may not be entirely covered by the coating materials, which act as a protective layer. The serotonin agonist-containing composition may thus degrade before being absorbed by the intestines into the bloodstream of the animals. On the other hand, if the content of the coating materials exceeds 15 wt %, the active ingredients in the composition may not effectively be released from the composition. Thus, the intended regulation of calcium mobilization would not be achieved.
- TPI1-/-, and corresponding wild type control animals (C57BL/6J genetic background) were bred and maintained in our animal facility. All experiments were performed under protocols approved by the University of Cincinnati Institutional Animal Care and Use Committee. Plasma was collected for PTHrP assay from non-lactating wild type mice and both wild type and TPH1-/- animals on day 10 of lactation. Mammary gland tissues (#4 glands counted from most rostral) were collected for immunostaining from TPH1-/- animals and wild type controls on day 10 of lactation, and were fixed in 4% paraformaldehyde, before being paraffin embedded and sectioned.
- PTHrP IRMA. Plasma PTHrP levels were measured using a two-site immunoradiometric assay specific for PTHrP 1-86 (Becton Dickinson), following the manufacturer's instructions. The detection limit (blank serum +1 standard deviation) was 0.3 pM under the conditions of this assay.
- Cell culture. Primary bovine mammary epithelial cells grown in collagen gels were induced to differentiate by release of the gel from the substratum, and treating with lactogenic hormones as described (15,31). The mouse mammary epithelial cells (HC11) were maintained under growth medium conditions, and lactogen-induced by treatment of 3 day confluent cultures with prolactin, insulin, and cortisol as previously described (17).
- Primary bovine mammary epithelial cells (pBMEC) were obtained as a generous gift from Dr. Robert Collier at the University of Arizona and cultured as previously described (15,31).
- Quantitative real-time RT-PCR amplification. Total RNA was isolated using TRIreagent® (Molecular Research) following manufacturer's procedures. RNA quality was determined through spectrophometric methods on the Nanodrop 2000 (Thermo Scientific). A total of 1 pg was reverse transcribed using the QuantiTect reverse transcription kit (Qiagen). Quantitative real-time RT-PCR was performed using the Applied Biosystems Step One Plus system (Applied Biosystems) using fast SYBR green master mix (Applied Biosystems). The following conditions were utilized: 95'C for 20 sec. followed by 40 cycles of 95'C for 3 sec., 60'C for 30 sec.
- Immunohistochemistry and western blotting. PTHrP fluorescent immunostaining was performed using a 1:50dilution of goat anti-PTHrP (N-19; Santa Cruz Biotechnology) overnight at 4'C and 1:1000 dilution of the rabbit anti-goat Alexa Fluor 488 Fa(b) fragments (Invitrogen) for 30 min at room temperature on paraffin-embedded sections of mammary gland tissue collected from TPH1-/- and wild type (TPH1+/+) mice collected at day 10 of lactation. Nuclei were visualized using a 1:1000 dilution of TOPRO-3 (Invitrogen) for 20 min at room temperature. Fluorescence was visualized on a Zeiss LSM 10 confocal microscope.
- Statistical Analyses. Statistical significance was determined in each experiment by Analysis of Variance (ANOVA), with Bonferroni's post-hoc test for relevant differences among groups, or two-tailed Student's t-test, on logic-transformed data. The cell culture data are reported with the number of replicate dishes in a single experiment, and each experiment was repeated independently at least twice with similar results. Significance was accepted at P<0.05.
- 5-HT Induces PTHrP During Lactation. We examined PTHrP levels in mammary glands of TPH1 knockout (TPH1-/-) mice and their corresponding normal controls (TPH1+/+) at mid-lactation by immunostaining. In the mammary tissue in control mice (TPH1-/-), PTHrP was detected both in the cytoplasm of the secretory cells, and within the secretory deposits in the alveolar lumens (left panel). Staining was observed in occasional cells that bordered the luminal epithelium, which were most likely to be myoepithelium. PTHrP immunoreactivity was markedly less in the glands of TPH lactating mice (right panel).
- PTHrP was below the level of detectability in the blood plasma of non-lactating females, and was readily detectable during lactation
- The conversion of L-tryptophan to 5-hydroxytryptophan (5-HTP) is the rate-limiting step in 5-HT synthesis; therefore we injected 5-HTP to bypass the enzyme deficiency in TPH1 mice, and measured PTHrP plasma levels. The mice rescued with 5-HTP showed a time-dependent increase in plasma PTHrP (P < 0.0001, R = 0.92), demonstrating that TPH1 activity was necessary for PTHrP secretion during lactation.
- To determine whether PTHrP expression in mammary epithelial cells was directly responsive to 5-HT two cell models of lactogenic mammary epithelium were studied: lactogen-treated rodent HC11 cells, and primary bovine mammary epithelial cells embedded in floating collagen gels. In these models 5-HT induced PTHrP gene expression by 8-fold and 20-fold, respectively.
- Based on the foregoing results, studies were conducted to establish, in practice, that feeding a diet supplemented with 5-HTP would elevate circulating levels of serotonin (5-HT) and PTHrP. Rats were fed a diet supplemented with 0.2% 5-HTP, and circulating levels of 5-HT (serum) and PTHrP (plasma) in the rats fed 0.2% 5-HTP from d13 pregnancy through d9 lactation were compared to rats fed a control breeder diet. The 5-HTP supplemented diet resulted in elevation of 5-HT, and subsequently, elevation of PTHrP (see
Fig. 1 ) - Based on the foregoing results, studies were conducted to establish, in practice, that feeding a diet supplemented with 5-HTP would elevate circulating calcium levels in lactating animals. Serum and milk calcium concentrations were measured in rats fed a diet supplemented with 0.2% 5-HTP (n=15) from d13 pregnancy-d9 lactation, compared to rats fed a control (n=15) diet. Serum calcium concentrations were elevated by 5-HTP supplementation on d1 of lactation, and subsequently, milk calcium levels were elevated by 5-HTP on d9 of lactation (
Fig. 2 ). -
- 1. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS and Lian JB.Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29: 6: 811-821,2010.
- 2. Ardeshirpour L, Dann P, Adams DJ, Nelson T, VanHouten J, Horowitz MC and Wysolmerski JJ. Weaning triggers a decrease in receptor activator of nuclear factor-kappaB ligand expression, widespread osteoclast apoptosis, and rapid recovery of bone mass after lactation in mice. Endocrinology 148: 8: 3875-3886, 2007.
- 3. Bliziotes M. Update in serotonin and bone. J, Clin.Endocrino/.Metab. 95: 9: 4124-4132, 2010.
- 4. Bostwick JR, Guthrie SK and Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29: 1: 64-73, 2009.
- 5. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ and Stewart AF. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N.Engl.J.Med. 319:9: 556-563,1988.
- 6. Caplan RH, Wickus GG, Sloane K and Silva PD. Serum parathyroid hormone-related protein levels during lactation. J.Reprod.Med. 40: 3: 216-218, 1995.
- 7. Clines GA and Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev,Mol.Med. 10: e7, 2008.
- 8. DeMauro S and Wysolmerski J.Hypercalcemia in breast cancer: an echo of bone mobilization during lactation? J.Mammary Gland Biol.Neoplasia 10: 2: 157-167,2005.
- 9. Dobnig H, Kainer F, Stepan V, Winter R, Lipp R, Schaffer M, Kahr A, Nocnik S, Patterer G and Leb G, Elevated parathyroid hormone-related peptide levels after human gestation: relationship to changes in bone and mineral metabolism. J.Clin.Endocrinol.Metab, 80: 12: 3699-3707,1995,
- 10. Fiaschi-Taesch NM and Stewart AF. Minireview: parathyroid hormone-related protein as an intracrine factor -trafficking mechanisms and functional consequences. Endocrinology 144: 2: 407-411,2003.
- 11.Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S and Reith K. Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect. Tissue Res. 44 Suppl 1: 109-116,2003.
- 12. Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, Karamouzis M and Dimitriadis A. Osteopenia in children and adolescents with hyperprolactinemia. J.Pediatr,Endocrinol.Metab. 13:4: 439-441, 2000.
- 13. Graham TR, Agrawal KC and Abdel-Mageed AB. Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-El osteoblast-like cells. Cancer.Sct. 101: 1: 103-111,2010.
- 14. Guo Y, Tiedemann K, Khalil JA, Russo C, Siegel PM and Komarova SV. Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 43: 2: 386-393, 2008.
- 15. Hernandez LL, Limesand SW, Collier JL, Horseman ND and Collier RJ. The bovine mammary gland expresses multiple functional isoforms of serotonin receptors. JEndocrinol. 203: 1: 123-131,2009.
- 16. Horst RL, Goff JP and Reinhardt TA. Adapting to the transition between gestation and lactation: differences between rat, human and dairy cow. J.Mammary Gland Biol.Neopiasia 10:2: 141-156,2005.
- 17. Hou X, Bailey JP, Vomachka AJ, Matsuda M, Lockefeer JA and Horseman ND. Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is induced by prolactin and suppressed by progesterone in mammary epithelium. 141: 11:4278-83., 2000.
- 18. Huang W, Yang S, Shao J and Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front.Biosci. 12: 3068-3092, 2007.
- 19. Inman CK and Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J.Biol.Chem. 278: 49: 48684-48689, 2003.
- 20. Jackson JC, Cross RJ, Walker RF, Markesbery WR, Brooks WH and Roszman TL. Influence of serotonin on the immune response. Immunology 54: 3: 505-512, 1985.
- 21. Kim HJ, Kim JH, Bae SC, Choi JY, Kim HJ and Ryoo HM. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J.Biol.Chem. 278: 1: 319-326, 2003.
- 22. Kingsley LA, Fournier PG, Chirgwin JM and Guise TA. Molecular biology of bone metastasis. Mol. Cancer. Ther. 6: 10: 2609-2617, 2007.
- 23. Klein M, Weryha G, Dousset B, Aubert V, Kaminsky P and Leclere J. Physiological role of PTHrP. Ann.Endocrinol. (Paris) 56: 3: 193-204, 1995.
- 24. Komori T. Regulation of bone development and maintenance by Runx2. Front.Biosci, 13: 898-903, 2008.
- 25. Kovacs CS. Calcium and bone metabolism during pregnancy and lactation. J.Mammary Gland Biol.Neopiasia 10:2: 105-118,2005.
- 26. Kovacs CS and Chik CL. Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. J.Clin.Endocrinol. Metab. 80: 10: 3036-3042, 1995.
- 27. Liao J and McCauley LK. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev. 25: 4: 559-571, 2006.
- 28. Luparello C, Santamaria F and Schilling T. Regulation of PTHrP and PTH/PTHrP receptor by extracellular Ca2+ concentration and hormones in the breast cancer cell line 8701-BC.Biol.Chem. 381:4: 303•308, 2000.
- 29. Marshall AM, Nommsen-Rivers LA, Hernandez LL, Dewey KG, Chantry CJ, Gregerson KA and Horseman ND. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. J.Clin.Endocrinol.Metab. 95: 2: 837-846, 2010.
- 30. Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, Mistry M, Bailey JP, Nieport KM, Walther DJ, Bader M and Horseman ND. Serotonin regulates mammary gland development via an autocrine•paracrine loop. Dev. Cell. 6: 2: 193-203, 2004.
- 31.McGrath MF. A novel system for mammary epithelial cell culture. J.Dairy Sci. 70: 9: 1967-1980, 1987.
- 32. Misra M, Papakostas GI and Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J,Clin.Psychiatry 65: 12: 1607-18;quiz 1590, 1760-1,2004.
- 33. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Naf.Rev. Cancer. 2; 8: 584-593, 2002.
- 34. Murray RD, Horsfield JE, McCormick WD, Williams HJ and Ward D. Historical and current perspectives on the treatment, control and pathogenesis of milk fever in dairy cattle. Vet.Rec. 163: 19: 561-565, 2008.
- 35. Pai VP and Horseman ND. Regulation of epithelial turnover by serotonin through induction of cell loss. PLoS One 6: 2: e17028, 2011.
- 36. Pai VP and Horseman ND. Biphasic regulation of mammary epithelial resistance by serotonin through activation ofmultiple pathways. JBiol.Chem. 283:45:30901-30910,2008.
- 37. Pai VP, Marshall AM, Hernandez LL, Buckley AR and Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 11:6: R81, 2009.
- 38. Pai VP and Marshall AM. Intraluminal volume homeostasis: A common serotonergic mechanism among diverse epithelia. Communicative Integrative Biology 4:5:0-1, 2011.
- 39. Pirola CJ, Wang HM, Kamyar A, Wu S, Enomoto H, Sharifi B, Forrester JS, Clemens TL and Fagin JA. Angiotensin II regulates parathyroid hormone-related protein expression in cultured rat aortic smooth muscle cells through transcriptional and post-transcriptional mechanisms. J.Biol.Chem, 268: 3: 1987-1994, 1993,
- 40. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS and Lian JB.The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol.Cell. Biol. 25: 19: 8581-8591, 2005.
- 41. Rankin W, Grill V and Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer 80: 8 Suppl: 1564-1571, 1997.
- 42. Richard V, Rosol TJ and Foley J. PTHrP gene expression in cancer: do all paths lead to Ets? Clin.Rev.Eukaryot. Gene Expt. 15:2: 115-132,2005.
- 43. Shibli-Rahhal A and Schlechte J.The effects of hyperprolactinemia on bone and fat. Pituitary 12: 2: 96•104, 2009.
- 44. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J.Cell.Biochem. 96: 3: 484-489, 2005.
- 45. Sowers MF, Hollis BW, Shapiro B, Randolph J, Janney CA, Zhang D, Schork A, Crutchfield M, Stanczyk F and Russell-Aulet M. Elevated parathyroid hormone-related peptide associated with lactation and bone density loss. JAM4 276: 7; 549-554, 1996.
- 46. Stewart AF. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. JBone Miner.Res. 17: 5: 758•762, 2002.
- 47. Stiegler C, Leb G, Kleinert R, Warnkross H, Ramschak-Schwarzer S, Lipp R, Clarici G, Krejs GJ and Dobnig H. Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J,Bone Minev.Res. 10: 5: 751-759, 1995.
- 48. Stull MA, Pai V, Vomachka AJ, Marshall AM, Jacob GA and Horseman ND. Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions. Proc. Natl.Acad. Sci, USA, 104: 42: 16708-16713,2007.
- 49. Tai CJ, Wu AT, Chiou JF, Jan HJ, Wei HJ, Hsu CH, Lin CT, Chiu WT, Wu CW, Lee HM and Deng WP. The investigation of mitogenactivated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. BMC Cancer 10: 95, 2010.
- 50. Thiede MA. Parathyroid hormone-related protein: a regulated calcium-mobilizing product of the mammary gland. J. Dairy Sci. 77: 7: 1952-1963, 1994.
- 51. Thiede MA and Rodan GA. Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science 242: 4876: 278-280, 1988.
- 52. Uemura H, Yasui T, Umino Y, Yamada M, Kuwahara A, Matsuzaki T, Maegawa M and 1rahara M. Regulatory factors on parathyroid hormone-related peptide production by primary culture of lactating rat mammary gland. 37: 8: 463-467, 2005.
- 53. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, Lian JB,van Wijnen AJ, Stein JL and Stein GS. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J.Cell.Biochem. 109:4: 828-837, 2010.
- 54. VanHouten JN, Dann P, Stewart AF, Watson CJ, Pollak M, Karaplis AC and Wysolmerski JJ. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J.Clin.Invest. 112:9; 1429-1436,2003.
- 55. Wysolmerski JJ.Interactions between breast, bone, and brain regulate mineral and skeletal metabolism during lactation. Ann. NY Acad Sci, 1192:1:161-169,2010.
- 56. Ye Y, Falzon M, Seitz PK and Cooper CW. Overexpression of parathyroid hormone-related protein promotes cell growth in the rat intestinal cell line IEC-6. Regul, Pept. 99: 2-3: 169-17 4, 2001.
- It must be noted that, as used in this specification and the appended claims, the singular forms "a" "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a "colorant agent" includes two or more such agents.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.
- While it is apparent that the illustrative embodiments of the invention herein disclosed fulfill the objectives stated above, it will be appreciated that numerous modifications and other embodiments may be devised by one of ordinary skill in the art. Accordingly, it will be understood that the appended claims are intended to cover all such modifications and embodiments, which come within the spirit and scope of the present invention.
- It should be noted that, when employed in the present disclosure, the terms "comprises," "comprising," and other derivatives from the root term "comprise" are intended to be open-ended terms that specify the presence of any stated features, elements, integers, steps, or components, and are not intended to preclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof.
- As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention in virtually any appropriately detailed structure.
Claims (13)
- A pharmaceutical agent that increases serotonergic signaling for use in the prevention and/or treatment of periparturient hypocalcaemia (milk fever) in lactating female mammals.
- The pharmaceutical agent of claim 1, wherein the pharmaceutical agent is a serotonin receptor agonist, a serotonin releasing agent, a serotonin reuptake inhibitor, an inhibitor of serotonin degradation, or a precursor thereof.
- The pharmaceutical agent of claim 2, wherein the pharmaceutical agent is 5-Hydroxytryptophan.
- The pharmaceutical agent of claim 2, wherein the lactating female mammal is selected from the group consisting of bovine, ovine, porcine and humans and wherein the administration of the agent improves calcium mobilization of the lactating mammal.
- The pharmaceutical agent of claim 2, wherein the pharmaceutical agent is administered at the onset of lactation.
- The pharmaceutical agent of claim 3, wherein the effective daily dosages of 5-Hydroxytryptophan range between about 5 mg and about 10,000 mg.
- The pharmaceutical agent of claim 3, wherein the pharmaceutical agent is administered in an amount of approximately 50 mg/kg to 500 mg/kg.
- The pharmaceutical agent of claim 2, wherein the pharmaceutical agent is administered to the mammal until at least day 4 of the treatment.
- The pharmaceutical agent of claim 2, wherein the pharmaceutical agent is administered as a rumen-protected formulation and wherein the pharmaceutical agent administration causes an overall increase in ruminant serum calcium concentration in the periparturient period.
- The pharmaceutical agent of claim 2, further comprising a serotonin agonist or a salt thereof; and a stabilizer mixed with a suitable premix.
- A pharmaceutical agent that increases serotonergic signaling for use in maintaining calcium homeostasis in lactating female mammals.
- The pharmaceutical agent of claim 11, wherein the pharmaceutical agent is a serotonin receptor agonist, a serotonin releasing agent, a serotonin reuptake inhibitor, an inhibitor of serotonin degradation, or a precursor thereof.
- The pharmaceutical agent of claim 12, wherein the pharmaceutical agent increases PTHrP levels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591009P | 2012-01-26 | 2012-01-26 | |
PCT/US2013/023196 WO2013112873A2 (en) | 2012-01-26 | 2013-01-25 | Compositions and methods for improving lactation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2806871A2 EP2806871A2 (en) | 2014-12-03 |
EP2806871A4 EP2806871A4 (en) | 2016-07-20 |
EP2806871B1 true EP2806871B1 (en) | 2017-03-01 |
Family
ID=48874069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13740771.4A Active EP2806871B1 (en) | 2012-01-26 | 2013-01-25 | Compositions and methods for improving lactation |
Country Status (6)
Country | Link |
---|---|
US (2) | US9585870B2 (en) |
EP (1) | EP2806871B1 (en) |
BR (1) | BR112014018530A8 (en) |
CA (1) | CA2863222C (en) |
NZ (1) | NZ627895A (en) |
WO (1) | WO2013112873A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106414755B (en) | 2014-05-16 | 2022-11-11 | 生物技术时代公司 | Microbial pathway for the production of 5-hydroxytryptophan |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK159807C (en) * | 1989-02-27 | 1992-06-29 | Gunnar Kjems | APPLICATION OF CALCIUM-SUSTAINABLE EMULSIONS FOR THE PREPARATION OF ORAL AGENTS FOR PREVENTION OR TREATMENT OF CALCIUM LACK OF Cattle, especially by calving fever |
US5560920A (en) * | 1995-04-07 | 1996-10-01 | The United States Of America, As Represented By The Secretary Of Agriculture | Calcium formulations for prevention of parturient hypocalcemia |
ES2251361T3 (en) * | 1998-10-30 | 2006-05-01 | Rj Innovation | A METHOD OF PREVENTION OF PUERPERAL HYPOCALCEMIA IN ANIMALS AND COMPOSITIONS USED IN THE SAME. |
WO2003013495A1 (en) * | 2001-08-08 | 2003-02-20 | Smothers Don L | Formulation and method for reduction of stress in meat-producing animals |
WO2003014321A2 (en) * | 2001-08-10 | 2003-02-20 | The Rockefeller University | Compositions and methods for modulation of darpp-32 phosphorylation |
US7241797B2 (en) * | 2002-01-23 | 2007-07-10 | University Of Cincinnati | Method of increasing milk production |
WO2004028552A1 (en) * | 2002-09-25 | 2004-04-08 | Garvan Institute Of Medical Research | Method for inducing mammary epithelial cell differentiation |
US20070292493A1 (en) * | 2006-06-15 | 2007-12-20 | Brierre Barbara T | Pharmaceutical composition and method for the transdermal delivery of calcium |
US8133916B1 (en) * | 2009-03-10 | 2012-03-13 | Amelgo, LLC | Control of milk production and mammary involution |
-
2013
- 2013-01-25 NZ NZ627895A patent/NZ627895A/en unknown
- 2013-01-25 US US14/375,103 patent/US9585870B2/en active Active
- 2013-01-25 CA CA2863222A patent/CA2863222C/en active Active
- 2013-01-25 BR BR112014018530A patent/BR112014018530A8/en not_active Application Discontinuation
- 2013-01-25 WO PCT/US2013/023196 patent/WO2013112873A2/en active Application Filing
- 2013-01-25 EP EP13740771.4A patent/EP2806871B1/en active Active
-
2017
- 2017-01-20 US US15/411,093 patent/US20170128418A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
CA2863222C (en) | 2019-01-08 |
WO2013112873A3 (en) | 2015-06-18 |
EP2806871A4 (en) | 2016-07-20 |
CA2863222A1 (en) | 2013-08-01 |
US9585870B2 (en) | 2017-03-07 |
BR112014018530A2 (en) | 2017-06-20 |
WO2013112873A2 (en) | 2013-08-01 |
US20150031741A1 (en) | 2015-01-29 |
BR112014018530A8 (en) | 2017-07-11 |
NZ627895A (en) | 2015-11-27 |
US20170128418A1 (en) | 2017-05-11 |
EP2806871A2 (en) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Grummer | Nutritional and management strategies for the prevention of fatty liver in dairy cattle | |
Lei et al. | Nutritional and regulatory role of branched-chain amino acids in lactation | |
ES2687416T3 (en) | Agent to improve milk production and / or ruminant milk quality | |
Lucy et al. | Glucose infusion into early postpartum cows defines an upper physiological set point for blood glucose and causes rapid and reversible changes in blood hormones and metabolites | |
EP1378236B1 (en) | Agents against stress-induced diseases | |
CN103813790A (en) | GIP elevation inhibitor | |
JP2024074847A (en) | Feed additive composition and feed composition including the same | |
EP3133935B1 (en) | Use of an extract of scutellaria baicalensis comprising baicaline during the parturition period for stimulating lactation in livestock animals. | |
Dunshea et al. | Hyperinsulinaemia, supplemental protein and branched-chain amino acids when combined can increase milk protein yield in lactating sows | |
JP5346433B2 (en) | Livestock feed | |
Qu et al. | Differences of hormones involved in adipose metabolism and lactation between high and low producing Holstein cows during heat stress | |
US20170128418A1 (en) | Compositions and methods for improving lactation | |
Miao et al. | Chronic stress effects of high doses of vitamin D3 on Megalobrama amblycephala | |
US20240024358A1 (en) | Therapeutic clay compositions and methods of using | |
CN1278677C (en) | Composition for improving lipid metabolism | |
EP4331601A1 (en) | Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient | |
KR101203023B1 (en) | Preventive and/or therapeutic agent for calcipenia | |
US8852601B2 (en) | Method of stimulating growth and resistance to diseases of aquatic organisms | |
Tao et al. | Effect of energy sources on plasma insulin and nitrogen metabolism in sheep totally nourished by infusions | |
JP2017158539A (en) | Method for increasing milk yield and milk fat content of ruminant livestock | |
Dushkin | Correlation between mammary gland activity and fatty degeneration of liver in high productive cows | |
KR20240033706A (en) | A composition for preventing or treating diabetes | |
EP4052701A1 (en) | Composition for tgr5 activation | |
US9254304B2 (en) | Supplement composition and methods of use | |
JP2020152668A (en) | Glp-1 secretion promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140728 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
R17D | Deferred search report published (corrected) |
Effective date: 20150618 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602013017999 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031404500 Ipc: A23K0020142000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20160617 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A23K 20/142 20160101AFI20160613BHEP Ipc: A23K 40/35 20160101ALI20160613BHEP Ipc: A23K 50/10 20160101ALI20160613BHEP Ipc: A23L 33/175 20160101ALI20160613BHEP Ipc: A23K 50/30 20160101ALI20160613BHEP Ipc: A61K 31/405 20060101ALI20160613BHEP Ipc: A23K 50/75 20160101ALI20160613BHEP |
|
17Q | First examination report despatched |
Effective date: 20160826 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20161104 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20170103 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 870253 Country of ref document: AT Kind code of ref document: T Effective date: 20170315 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013017999 Country of ref document: DE Ref country code: CH Ref legal event code: NV Representative=s name: LEMAN CONSULTING S.A., CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170301 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 870253 Country of ref document: AT Kind code of ref document: T Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170601 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170602 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170601 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170703 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170701 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013017999 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
26N | No opposition filed |
Effective date: 20171204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: IP PARTNERS J. WENGER, CH |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170301 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231211 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20231212 Year of fee payment: 12 Ref country code: FR Payment date: 20231206 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231208 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231211 Year of fee payment: 12 Ref country code: CH Payment date: 20240201 Year of fee payment: 12 |